Upconversion luminesce materials are promising for widespread application ranging from optical devices to biodetection and cancer therapy, the near-infrared light excited upconversion materials are attracting much research attention. Researchers have achieved an ultra-strong and ultra-pure red upconversion in erbium and ytterbium co-doped lutetium oxyfluorides through size and morphology control. These nanoparticles, with extremely strong and pure upconversion are promising candidates as novel luminescent reagents for high-contrast bio-imaging and bio-labeling.
Biomineralization is the formation of inorganic materials in a biological environment, as it is found in bones, teeth and shells. Certain biominerals are also often associated with pathogeneses of tissues. The correlation of the composition of biominerals with pathogeneses of tissues has not been investigated systematically. In new work, researchers examine how the composition of biominerals correlates with the production of inflammatory cytokines associated with the stimulation of intracellular DNA sensors and by biominerals themselves.
Supramolecular chemistry deals with molecular building-blocks that interact with each other in a dynamic manner, similar to what is seen in nature. Taking advantage of this, several 'smart' materials have been developed for biomedical applications by careful design of these building-blocks. These materials have especially interesting properties like self-healing and responsiveness to light and electricity. Researchers have now explored the possibility of developing a bacterial strain with the ability to interact dynamically with a popular supramolecular building-block.
A novel nanoparticle blood test detects an overall increase of human immunoglobulin G (IgG), including the tumor-specific autoantibodies, adsorbed to a gold nanoparticle surface. While this test may not be able to identify the specific type of cancer, it may potentially be able to detect early stage tumor-induced immune responses associated with a broad spectrum of cancer types, making this test potentially a universal screening test for cancer risk assessment.
Typically, in clinical formulations of Magnetic Resonance Imaging (MRI) contrast agents, gram quantities of Gd(III) are needed to achieve sufficiently high contrast for examination. That's why the research imaging community is interested in developing new formulations of contrast agents able to bridge the gap between high contrast imaging of contrast agents dosed at low concentrations.
In new work, researchers report a new class of gold nanoconjugates that exhibit exceptionally high relaxivities at both low and high field strengths.
Trying to develop chemical free disinfection techniques, researchers are currently exploring the effectiveness of a nanotechnology based intervention method for the inactivation of foodborne and spoilage microorganisms on fresh produce and on food production surfaces. This method utilizes Engineered Water Nanostructures (EWNS) generated by electrospraying of water. These EWNS are 25 nm in diameter; remain airborne in indoor conditions for hours; contain Reactive Oxygen Species (ROS); have very strong surface charge (on average 10 electrons per structure) and have the ability to interact and inactivate pathogens by destroying their membrane.
Researchers have developed a magnetic bead based sensor that combines magnetic separation (MS) and magnetic relaxation switch (MRS) for one-step detection of bacteria and viruses with high sensitivity and reproducibility. Compared to conventional assays for detection of bacteria and viruses, this novel MS-MRS assay is easy to operate without laborious pre-treatment, purification and can be adaptable to point-of-care tests easily.
Historically, the approval of Doxil as the very first nanotherapeutic product in 1995 is generally regarded as the dawn of nanomedicine for human use. Although numerous products classified as nanomedicine products have indeed appeared over the past decade, such products have not exactly revolutionized treatment paradigms as envisaged earlier. In particular no molecular machine or nanorobot has yet entered clinical trials, although research in these areas is picking up pace.